Zenas BioPharma, Inc.
ZBIO
$7.80
-$0.63-7.47%
| Weiss Ratings | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.38% | |||
| 30-Day Total Return | -0.13% | |||
| 60-Day Total Return | -23.00% | |||
| 90-Day Total Return | -37.35% | |||
| Year to Date Total Return | -13.43% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -67.89% | |||
| 52-Week Low % Change | 44.60% | |||
| Price | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $26.25 | |||
| 52-Week Low Price | $5.83 | |||
| 52-Week Low Price (Date) | Jan 28, 2025 | |||
| 52-Week High Price (Date) | Oct 23, 2024 | |||
| Valuation | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 352.37M | |||
| Enterprise Value | 2.61M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -48.39 | |||
| Earnings Per Share Growth | 95.37% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 70.72 | |||
| Price/Book (Q) | 1.13 | |||
| Enterprise Value/Revenue (TTM) | 0.52 | |||
| Price | $7.80 | |||
| Enterprise Value/EBITDA (TTM) | -0.02 | |||
| Enterprise Value/EBIT | -0.02 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 41.93M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 271 2954 | |||
| Address | 852 Winter Street Waltham, MA 02451 | |||
| Website | zenasbio.com | |||
| Country | United States | |||
| Year Founded | 2019 | |||
| Profitability | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -3,277.74% | |||
| Profit Margin | -3,139.74% | |||
| Management Effectiveness | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -46.76% | |||
| Return on Equity | -- | |||
| Income Statement | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.00M | |||
| Total Revenue (TTM) | 5.00M | |||
| Revenue Per Share | $0.12 | |||
| Gross Profit (TTM) | -134.14M | |||
| EBITDA (TTM) | -163.75M | |||
| EBIT (TTM) | -163.89M | |||
| Net Income (TTM) | -156.99M | |||
| Net Income Avl. to Common (TTM) | -156.99M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -113.95% | |||
| EPS Diluted (TTM) | -48.39 | |||
| EPS Diluted Growth (Q YOY) | 92.13% | |||
| Balance Sheet | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 350.77M | |||
| Cash Per Share (Q) | $8.37 | |||
| Total Current Assets (Q) | 355.92M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 312.46M | |||
| Current Ratio (Q) | 6.212 | |||
| Book Value Per Share (Q) | $7.48 | |||
| Total Assets (Q) | 369.97M | |||
| Total Current Liabilities (Q) | 57.29M | |||
| Total Debt (Q) | 1.00M | |||
| Total Liabilities (Q) | 57.51M | |||
| Total Common Equity (Q) | 312.46M | |||
| Cash Flow | ZBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -30.55M | |||
| Cash from Financing (TTM) | 412.96M | |||
| Net Change in Cash (TTM) | 262.89M | |||
| Levered Free Cash Flow (TTM) | -62.95M | |||
| Cash from Operations (TTM) | -119.67M | |||
